While Seres has seen explosive headcount growth over the past year, the company is planning for more. Seres is expanding its physical footprint in Cambridge and hiring more staff.
January 28, 2016 By Mark Terry, BioSpace.com Breaking News Staff Cambridge, Mass.-based Biogen Inc. (BIIB) announced its 2015 financial and fourth-quarter reporting yesterday, citing $10.8 billion in annual revenues, an increase of 11 percent over 2014. Biogen exceeded analysts expectations, who were predicting a revenue increase of about 9 percent. Net income was $3.6 […]
With the 2015 record-breaking biopharma merger-and-acquisition period about to come to an end, analysts are tuning their crystal balls to 2016. So far this year—not quite done yet—there has been $667.5 billion in healthcare mergers and acquisitions, according to Dealogic. Next year is likely to continue a trend that started, or at least accelerated, last […]
AstraZeneca enters into agreement with Perrigo for rights to Entocort in the US Divestment further sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015 23 November 2015 AstraZeneca today announced that it has entered into an agreement with Perrigo Company plc for the divestment of US rights […]
Johnson & Johnson’s Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn’s disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. Stelara, a biotech medicine that blocks inflammation, is approved to treat the skin condition […]
A new electronic drug capsule engineered to deliver medications directly to the colon could potentially offer a more effective and cheaper option for treating people with gastrointestinal conditions, according to researchers at Purdue University in Indiana. The device is comprised of two parts, one carrying a drug payload and the other housing electronics designed […]
LONDON (Reuters) – Cut-price versions of expensive biotech drugs are gaining ground in Europe, following surprisingly steep price discounts offered on the first copy of a complex antibody medicine for rheumatoid arthritis and Crohn’s disease. The potential for so-called “biosimilars” to take business from pricey original brands is grabbing the attention of both healthcare providers, […]
Biogen, Inc., headquartered in Cambridge, Mass., announced today that it licensed MT-1303 from Mitsubishi Tanabe Pharma Corporation, located in Osaka, Japan. MT-1303 is being investigated in a number of autoimmune disorders, including multiple sclerosis (MS), ulcerative colitis, Crohn’s disease and others. Biogen will obtain worldwide rights to MT-1303, excluding Asia. It will oversee global […]